Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep840 | Late Breaking | ECE2021

Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: A pilot study

Chiloiro Sabrina , Giampietro Antonella , Angelini Flavia , Paolo Mattogno Pier , Tartaglione Tommaso , Lauretti Liverana , Pontecorvi Alfredo , De Marinis Laura , Bianchi Antonio

IntroductionPrimary autoimmune hypophysitis (PAHs) is a rare inflammatory disease of the pituitary gland. Although largely investigated, the pathogenesis of PAH is not completely clarified. We aimed to investigate the immune response in PAHs.Material and methodsSerum anti-pituitary and anti-hypothalamus antibodies (respectively APAs and AHAs) were investigated though an indirect immunofluorescence on monkey h...

ea0081ep771 | Pituitary and Neuroendocrinology | ECE2022

The management of hypophysitis in Covid-19

Menotti Sara , Veleno Miriam , Giampietro Antonella , Chiloiro Sabrina , Mattogno Pier Paolo , Giorgio D'Alessandris Quintino , Lauretti Liverana , Gaudino Simona , Doglietto Francesco , Pontecorvi Alfredo , Marinis Laura De , Bianchi Antonio

Introduction: Literature has already described some cases of hypophysitis related to acute respiratory syndrome coronavirus 2 (SARS-Cov2). The pituitary is indeed target for the virus due to the angiotensin-converting-enzyme-2 expression. Hypophysitis patients present with mass effect and pituitary dysfunction related symptoms. ACTH and TSH deficiencies are the most reported, along with central diabetes insipidus (CDI). The best way to manage these hypophysitis is still undefi...

ea0090p409 | Pituitary and Neuroendocrinology | ECE2023

Inflammatory infiltrate in wild-type and non-wild-type GNAS somatotropinomas

Chiloiro Sabrina , Cicia Martina , Giampietro Antonella , Gessi Marco , Lauretti Liverana , Paolo Mattogno Pier , Carlino Angela , Olivi Alessandro , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Doglietto Francesco , Bianchi Antonio

Introduction: Somatotropinomas are benign pituitary tumors with heterogeneous biological and clinical behavior. The tumor microenvironment (TME) is an environment generated by the interaction between tumor cells and the host immune system. It affects both the behavior of the tumor and the outcome of the therapy. The GNAS gene encodes the alpha subunit of G proteins associated with hormone receptors such as TSH, PTH, GHRH, FSH/lH, ACTH. Mutation of this gene has been associated...

ea0090p424 | Pituitary and Neuroendocrinology | ECE2023

The acro-TIME score: a new clinical, pathological and immune integrative approach to early identify acromegaly patients resistant to treatment with first generation somatostatin ligands

Chiloiro Sabrina , Giampietro Antonella , Gessi Marco , Lauretti Liverana , Mattogno Pierpaolo , Costanza Flavia , Carlino Angela , Olivi Alessandro , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Doglietto Francesco , Bianchi Antonio

Somatotropinomas are benign pituitary tumors, with a heterogenous biological and clinical behavior. Tumor microenvironment reflects the interaction between tumor cells and the host immune system and may regulate tumor behavior and therapy outcome. We develop a scoring system that includes clinical, pathological and immune markers to early identify fg-SRLs resistant acromegaly pts. 43 acromegaly pts were included according the following criteria (1) first line treatment with su...

ea0090p438 | Pituitary and Neuroendocrinology | ECE2023

The Role of the GH Receptor Polymorphism as Prognostic Factor of Vertebral Fractures in Acromegaly Patients Resistant to First Generation SSAs and Treated with GH Receptor Antagonist or Second-Generation Somatostatin Ligand

Costanza Flavia , Chiloiro Sabrina , Giampietro Antonella , Mattogno Pierpaolo , Amato Infante , Angelini Flavia , Lauretti Liverana , Olivi Alessandro , Pontecorvi Alfredo , Doglietto Francesco , De Marinis Laura , Bianchi Antonio

Acromegaly is associated with skeletal fragility and an increased prevalence of vertebral fractures (VF). In recent years several authors have tried to investigate the markers that can predict the risk of bone fragility in this endocrine disorder. Two different isoforms of the GH receptor (GHR) have been described so far, which differ in the presence or absence of a transcript of exon 3 of the GHR gene. Both isoforms produce a functional receptor, but the exon 3-deleted isofor...

ea0049ep997 | Pituitary - Clinical | ECE2017

Localization of the catheters during Bilateral sampling of the inferior petrosal sinuses can impact diagnostic power?

Chiloiro Sabrina , Pedicelli Alessandro , Valente Iacopo , Tartaglione Tommaso , Bianchi Antonio , Giampietro Antonella , Bima Chiara , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , De Marinis Laura

Introduction: Bilateral sampling of the inferior petrosal sinuses (IPSS) is considerate actually the best diagnostic test for Cushing.Patients and methods: We retrospectively reviewed our series of patients undergone IPSS for Cushing disease and we compared the difference between central and peripheral ACTH gradient in basal condition and after CRH stimulation in cases of localization of the tip of the catheters inside the inferior petrosal sinus or at t...

ea0056p751 | Neuroendocrinology | ECE2018

Efficacy and safety of a combinated pasireotide lar, pegvisomant and cabergoline treatment in four cases of aggressive somatotrophinomas

Bima Chiara , Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Piacentini Serena , Milardi Domenico , Tartaglione Tommaso , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , Marinis Laura De

Introduction: A significant number of GH-secreting pituitary adenomas show an aggressive behavior, therefore, when uncontrolled acromegaly persists, a pharmaceutical combination may improve biochemical control, with reduction of disease morbidity and mortality. We aimed to describe the clinical features of four patients successfully treated with a pharmacological combination of pasireotide LAR, pegvisomant and cabergoline.Case reports: Acromegaly was dia...

ea0056p875 | Pituitary - Clinical | ECE2018

Efficacy of pasireotide lar in first line somatostatin analogue resistant acromegaly patients: experience from a large and single centre Italian cohort

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Tartaglione Tommaso , Bima Chiara , Piacentini Serena , Mirra Federica , Donfrancesco Federico , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , De Marinis Laura

Introduction: Pasireotide Lar is a new generation long-acting somatostatin multireceptor ligand, approved for the treatment of first line somatostatin analogue resistant patients. We aimed to review Pasireotide Lar efficacy data, in our series of patients affected by aggressive acromegaly.Patients: A retrospective longitudinal study was conducted on patients with aggressive acromegaly, resistant to first-line somatostatin analogues (SSA) and on treatment...

ea0093oc27 | Oral communication 4: Pituitary and Neuroendocrinology | EYES2023

The role of the GH receptor polymorphisms as a prognostic factor of vertebral fractures in acromegalic patients resistant to first-generation SSAs and treated with Pegvisomant or Pasireotide Lar

Costanza Flavia , Chiloiro Sabrina , Giampietro Antonella , Mattogno Pier Paolo , Infante Amato , Angelini Flavia , Lauretti Liverana , Olivi Alessandro , Pontecorvi Alfredo , Doglietto Francesco , De Marinis Laura , Bianchi Antonio

Background: Acromegaly is associated with skeletal fragility and increased prevalence of vertebral fractures (VF). In recent years several authors tried to investigate predictor markers of bone fragility risk in this endocrine disorder. Two isoforms of GH receptor (GHR) have been described, which differ in the presence or absence of a transcript of exon 3 of the GHR gene. Both isoforms produce a functional receptor, but the exon 3-deleted isoforms (d3-GHR) have greater sensiti...